Cost-effectiveness of prion filtration of red blood cells to reduce the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease in the Republic of Ireland

Transfusion

Volumn 52, Issue 11, 2012, Pages 2285-2293

  Teljeur, Conor ^a   Flattery, Martin ^a   Harrington, Patricia ^a   O'Neill, Michelle ^a   Moran, Patrick S ^a   Murphy, Linda ^a   Ryan, Máirín ^a  

^a HEALTH INFORMATION AND QUALITY AUTHORITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; ERYTHROCYTE; FILTRATION; HUMAN; IRELAND; MORTALITY; PRION FILTRATION; RISK REDUCTION;

BLOOD SAFETY; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; CREUTZFELDT-JAKOB SYNDROME; FILTRATION; HEALTH POLICY; HUMANS; IRELAND; MODELS, ECONOMETRIC; PREVALENCE; PRIONS; RISK FACTORS;

EID: 84869234833     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03637.x     Document Type: Article

References (35)

1. US Department of Health and Human Services, Centers for Disease Control and Prevention. Chronic wasting disease [Internet]. CDC; 2011. [cited 2011 Jan 21]. Available from: URL: http://www.cdc.gov/ncidod/dvrd/cwd/
2. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari, M, Hofman A, Smith, PG,. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5.
3. Hilton DA,. Pathogenesis and prevalence of variant Creutzfeldt-Jakob disease. J Pathol 2006; 208: 134-41.
4. European Creutzfeldt Jakob Disease Surveillance Network. Current data (August 2011) [Internet]. EUROCJD; 2011. [cited 2011 Aug 31]. Available from: URL: http://www.eurocjd.ed.ac.uk
5. Knight R,. The risk of transmitting prion disease by blood or plasma products. Transfus Apher Sci 2010; 43: 387-91.
6. Murphy CV, Eakins E, Fagan J, Croxon H, Murphy WG,. In vitro assessment of red-cell concentrates in SAG-M filtered through the MacoPharma P-CAPT prion-reduction filter. Transfus Med 2009; 19: 109-16.
7. Orru CD, Wilham JM, Raymond LD, Kuhn F, Schroeder B, Raeber AJ, Caughey B,. Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. Mbio 2011; 2: e00078-11.
8. Edgeworth JA, Farmer M, Sicilia A, Tavares P, Beck J, Campbell T, Lowe J, Mead S, Rudge P, Collinge J, Jackson GS,. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 2011; 377: 487-93.
9. Gregori L, Gurgel PV, Lathrop JT, Edwardson P, Lambert BC, Carbonell RG, Burton SJ, Hammond DJ, Rohwer RG,. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006; 368: 2226-30.
10. Cancelas JA, Rugg N, Pratt PG, Worsham DN, Pehta JC, Banks K, Davenport RD, Judd WJ,. Infusion of P-Capt prion-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of neoantigen formation. Transfusion 2011; 51: 2228-36.
11. Health Information and Quality Authority. Guidelines for the economic evaluation of health technologies in Ireland. Dublin: HIQA; 2010.
12. Wells AW, Llewelyn CA, Casbard A, Johnson AJ, Amin M, Ballard S, Buck J, Malfroy M, Murphy MF, Williamson LM,. The EASTR Study: indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the National Blood Service. Transfus Med 2009; 19: 315-28.
13. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, Penney M, Hegazy D, Ironside JW,. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 733-9.
14. Clarke P, Ghani AC,. Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. J R Soc Interface 2005; 2: 19-31.
15. Irish Blood Transfusion Service. Annual report 2009. Dublin: Irish Blood Transfusion Service; 2010.
16. Spongiform Encephalopathy Advisory Committee (SEAC) (UK). SEAC position statement on TSE infectivity in blood [Internet]. SEAC Website; 2008. [cited 2010 Apr 26]. Available from: URL: http://webarchive.nationalarchives.gov.uk/ 20110316162913/http://www.seac.gov.uk/statements/statement0806.htm
17. Gregori L, McCombie N, Palmer D, Birch P, Sowemimo-Coker SO, Giulivi A, Rohwer RG,. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004; 364: 529-31.
18. Wiltshire M, Thomas S, Scott J, Hicks V, Haines M, Cookson P, Garwood M, Cardigan R,. Prion reduction of red blood cells: impact on component quality. Transfusion 2009; 50: 970-9.
19. Zou S, Fang CT, Schonberger LB,. Transfusion transmission of human prion diseases. Transfus Med Rev 2008; 22: 58-69.
20. Alperovitch A, Zerr I, Pocchiari M, Mitrova E, Cuesta JDP, Hegyi I, Collins S, Kretzschmar H, van Duijn C, Will RG,. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 1999; 353: 1673-4.
21. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM,. Updated projections of future vCJD deaths in the UK. BMC Infect Dis 2003; 3: 4.
22. Turner ML, Ludlam CA,. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009; 144: 14-23.
23. Boelle PY, Cesbron JY, Valleron AJ,. Epidemiological evidence of higher susceptibility to vCJD in the young. BMC Infect Dis 2004; 4: 26.
24. Garske T, Ghani AC,. Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK. PLoS ONE 2010; 5: e15626.
25. Gregori L, Lambert BC, Gurgel PV, Gheorghiu L, Edwardson P, Lathrop JT, Macauley C, Carbonell RG, Burton SJ, Hammond D, Rohwer RG,. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands. Transfusion 2006; 46: 1152-61.
26. Knight R,. The diagnosis of prion diseases. Parasitology 1998; 117 (Suppl): S3-11.
27. R Development Core Team. R: a language and environment for statistical computing [Internet]. Vienna. 2010. [cited 2010 Oct 5]. Available from: URL: http://www.R-project.org
28. Borkent-Raven BA, Janssen MP, van der Poel CL, de Wit GA, Bonsel GJ, van Hout BA,. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands. Transfusion 2009; 49: 311-9.
29. Jackson BR, Busch MP, Stramer SL, AuBuchon JP,. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-9.
30. Korves CT, Goldie SJ, Murray MB,. Cost-effectiveness of alternative blood-screening strategies for West Nile virus in the United States. PLoS Med 2006; 3: e21.
31. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC,. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86: 28-40.
32. Pereira A,. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. Transfusion 2003; 43: 192-201.
33. van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ,. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002; 83: 146-55.
34. Harney MS, Ghani AC, Donnelly CA, Walsh RM, Walsh M, Howley R, Brett F, Farrell M,. vCJD risk in the Republic of Ireland. BMC Infect Dis 2003; 3: 28.
35. Gregori L, Yang H, Anderson S,. Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood. Transfusion 2011; 51: 2596-602.